“20 years of research has shown that Lysine lowers glucose and glycated proteins. Zinc lowers glucose and glycated proteins and improves the lipid profile. Vitamin C lowers glucose and HbA1c.”Read the article
Founder & CEO of Lysulin, Inc.
Dr. Burd has over 30 years of experience in glucose monitoring technology. He was the founder of DexCom, where he directed the company’s work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes. DexCom has a market capitalization of more than $5 billion. Previously, Dr. Burd was CEO of Occulair, MiraMedica and LXN. He has authored and co-authored numerous articles and his work in the medical and biotechnology field has led to the filing and ownership of 23 patents, in addition to the development of many innovative medical products. He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin.